65,836 XNAS Volume
XNAS 21 Apr, 2025 12:15 PM (EDT)
Delcath Systems Inc Key Metrics
Select
All financials are in USD Million and price data in USD
VIEW MORE
Low Financial Strength
Expensive Valuation
Technically Neutral
Momentum Trap
These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks.
View Similar
Embed DVM
Check Before You Buy
VIEW FULL CHECKLISTHigh rank
11Positive10Negative
52.4% Pass in checklist
Check P/E Buy Sell Zone
This stock has negative PE
Delcath Systems Inc Stock Price Analysis
Day Price Range | 11.1 (LTP) 1111.6 LowHigh |
Week Price Range | 11.1 (LTP) 10.811.8 LowHigh |
Month Price Range | 11.1 (LTP) 9.814.6 LowHigh |
52 Week Price Range | 11.1 (LTP) 4.917 LowHigh |
Delcath Systems Inc Live Price Chart
Switch to TradingView
Fetching data ...
Revenue forecast
Consensus Recommendation
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get Delcath Systems Inc Stock Analysis
Delcath Systems Inc stock analysis with key metrics, changes, and trends.
Delcath Systems Inc Metric | VALUE | CHANGE % | TREND | ANALYSIS | |
---|---|---|---|---|---|
Annual Revenue | $37.2 M | 1701.69% | positive |
| |
Annual Net Profit | $26.39 M | 44.66% | positive |
| |
Price to Earning Ratio | -14.12 | - | negative |
| |
Stock Price | $11.14 | 128.75% | positive |
| |
Quarterly Revenue | $15.1 M | 2701.48% | positive |
| |
Quarterly Net profit | $3.4 M | 69.49% | positive |
| |
Debt to Equity Ratio | 0.02 | - | positive |
| |
Return on Equity(ROE) | -62.44 % | -62.44% | negative |
| |
Mutual Fund Holding | 11.43 % | 1.63% | positive |
| |
Promoter Share Holding | 12.17 % | 0% | neutral |
| |
Institutional Holding | 41.43 % | 0% | negative |
|
Loading data..
Delcath Systems Inc - Company Profile
What does Delcath Systems Inc do?
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Delcath Systems Inc Management structure
All Gross Remunerations are in USD
Delcath Systems Inc Board of directors
All Gross Remunerations are in USD